Real-world study of Trulicity shows improved adherence and persistence in type 2 diabetes.- Eli Lilly

New real-world data showed Trulicity (dulaglutide), from Eli Lilly, had significantly higher adherence and longer persistence compared to weekly injections of semaglutide or exenatide (BCise pen) in people with type 2 diabetes new to GLP-1 receptor agonist (RA) treatment. The real-world study comparing adherence and persistence used U.S. claims data of people with type 2 diabetes initiating weekly injectable treatment with Trulicity, semaglutide or exenatide. Matched cohorts were well balanced for characteristics such as age, gender, adapted Diabetes Complications Severity Index (aDCSI) score and select comorbidities. At six months, people taking Trulicity showed higher adherence and persistence than those taking semaglutide or exenatide. Further, significantly fewer people discontinued treatment with Trulicity compared to semaglutide or exenatide. In the study of Trulicity versus injectable semaglutide, adherence figures were 59.7 percent (Trulicity) versus 42.7 percent (semaglutide). For persistence: 143.6 days (Trulicity) versus 129.9 days (semaglutide) and for treatment discontinuation: 30.8 percent (Trulicity) versus 40.8 percent (semaglutide). Finally, in the study of Trulicity versus exenatide, the figures for adherence were: 58.1 percent (Trulicity) versus 40.3 percent (exenatide) and for persistence: 142 days (Trulicity) versus 121.4 days (exenatide). Finally the rate of treatment discontinuation was 32.1 percent (Trulicity) versus 49.4 percent (exenatide). The data were presented during the American Diabetes Association's (ADA) 80th Scientific Sessions.